Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis

Next Previous
X
Search
Trial Profile

A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gusacitinib (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Asana BioSciences; Kirilys Therapeutics

    • Most Recent Events

    • 26 Jul 2019 Results published in the Journal of Allergy and Clinical Immunology.
    • 28 Mar 2019 Results assessing efficacy, safety, pharmacokinetics and on systemic biomarkers of ASN002, published in the British Journal of Dermatology.
    • 19 Jul 2018 According to an Asana BioSciences media release, Dr. Robert Bissonnette is the President of Innovaderm Research, Montreal, Canada and a lead investigator for the ASN002 Phase 1b and Phase 2b RADIANT study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top